Anti-IL-20 monoclonal antibody suppresses breast cancer progression and bone osteolysis in murine models

Journal of Immunology

Volumn 188, Issue 4, 2012, Pages 1981-1991

  Hsu, Yu Hsiang ^a   Hsing, Chung Hsi ^b   Li, Chien Feng ^b   Chan, Chien Hui ^a   Chang, Ming Chung ^a   Yan, Jing Jou ^a   Chang, Ming Shi ^a  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b CHI MEI MEDICAL CENTER   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CATHEPSIN G; CATHEPSIN K; GELATINASE B; IMMUNOGLOBULIN G; INTERLEUKIN 20; INTERLEUKIN 20 ANTIBODY; MACROPHAGE ELASTASE; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE DENSITY; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CANCER STAGING; CANCER SURVIVAL; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; ENZYME REGULATION; ENZYME REPRESSION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MICRO-COMPUTED TOMOGRAPHY; MOUSE; NONHUMAN; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, MONOCLONAL; BONE AND BONES; BONE NEOPLASMS; BREAST; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CATHEPSIN G; CATHEPSIN K; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DISEASE PROGRESSION; FEMALE; HUMANS; INTERLEUKINS; MATRIX METALLOPROTEINASE 12; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED BALB C; NEOPLASM METASTASIS; OSTEOLYSIS;

EID: 84863165532     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1102843     Document Type: Article

References (44)

1. Mundy, G. R., and D. R. Bertolini. 1986. Bone destruction and hypercalcemia in plasma cell myeloma. Semin. Oncol. 13: 291-299. (Pubitemid 17204707)
2. Guise, T. A. 2000. Molecular mechanisms of osteolytic bone metastases. Cancer 88(12, Suppl)2892-2898. (Pubitemid 30413169)
3. Mundy, G. R. 2002. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat. Rev. Cancer 2: 584-593. (Pubitemid 37328925)
4. Romas, E., M. T. Gillespie, and T. J. Martin. 2002. Involvement of receptor activator of NFkappaB ligand and tumor necrosis factor-alpha in bone destruction in rheumatoid arthritis. Bone 30: 340-346. (Pubitemid 34154863)
5. Chapurlat, R., and P. J. Meunier. 1998. [Bisphosphonates and bone remodeling: effectiveness in Paget's disease, fibrous dysplasia and osteoporosis] Rev. Chir. Orthop Repar. Appar. Mot. 84: 743-751.
6. Chirgwin, J. M., and T. A. Guise. 2000. Molecular mechanisms of tumor-bone interactions in osteolytic metastases. Crit. Rev. Eukaryot. Gene Expr. 10: 159-178.
7. Delaissé, J. M., M. T. Engsig, V. Everts, M. del Carmen Ovejero, M. Ferreras, L. Lund, T. H. Vu, Z. Werb, B. Winding, A. Lochter, et al. 2000. Proteinases in bone resorption: obvious and less obvious roles. Clin. Chim. Acta 291: 223-234. (Pubitemid 30089766)
8. Saftig, P., E. Hunziker, O. Wehmeyer, S. Jones, A. Boyde, W. Rommerskirch, J. D. Moritz, P. Schu, and K. von Figura. 1998. Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. Proc. Natl. Acad. Sci. USA 95: 13453-13458. (Pubitemid 28522993)
9. Wilson, T. J., K. C. Nannuru, M. Futakuchi, A. Sadanandam, and R. K. Singh. 2008. Cathepsin G enhances mammary tumor-induced osteolysis by generating soluble receptor activator of nuclear factor-kappaB ligand. Cancer Res. 68: 5803-5811.
10. Chertov, O., H. Ueda, L. L. Xu, K. Tani, W. J. Murphy, J. M. Wang, O. M. Howard, T. J. Sayers, and J. J. Oppenheim. 1997. Identification of human neutrophil-derived cathepsin G and azurocidin/CAP37 as chemoattractants for mononuclear cells and neutrophils. J. Exp. Med. 186: 739-747. (Pubitemid 27381538)
11. Charafe-Jauffret, E., C. Tarpin, P. Viens, and F. Bertucci. 2008. Defining the molecular biology of inflammatory breast cancer. Semin. Oncol. 35: 41-50. (Pubitemid 351282395)
12. Kozlow, W., and T. A. Guise. 2005. Breast cancer metastasis to bone: mechanisms of osteolysis and implications for therapy. J. Mammary Gland Biol. Neoplasia 10: 169-180. (Pubitemid 41031006)
13. Heinrich, P. C., I. Behrmann, G. Müller-Newen, F. Schaper, and L. Graeve. 1998. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem. J. 334: 297-314. (Pubitemid 28448572)
14. Nicolini, A., A. Carpi, and G. Rossi. 2006. Cytokines in breast cancer. Cytokine Growth Factor Rev. 17: 325-337. (Pubitemid 44572877)
15. Blumberg, H., D. Conklin, W. F. Xu, A. Grossmann, T. Brender, S. Carollo, M. Eagan, D. Foster, B. A. Haldeman, A. Hammond, et al. 2001. Interleukin 20: discovery, receptor identification, and role in epidermal function. Cell 104: 9-19. (Pubitemid 32144968)
16. Pestka, S., C. D. Krause, D. Sarkar, M. R. Walter, Y. Shi, and P. B. Fisher. 2004. Interleukin-10 and related cytokines and receptors. Annu. Rev. Immunol. 22: 929-979. (Pubitemid 38680445)
17. Wegenka, U. M. 2010. IL-20: biological functions mediated through two types of receptor complexes. Cytokine Growth Factor Rev. 21: 353-363.
18. Dumoutier, L., C. Leemans, D. Lejeune, S. V. Kotenko, and J. C. Renauld. 2001. Cutting edge: STAT activation by IL-19, IL-20 and mda-7 through IL-20 receptor complexes of two types. J. Immunol. 167: 3545-3549. (Pubitemid 32910793)
19. Wei, C. C., Y. H. Hsu, H. H. Li, Y. C. Wang, M. Y. Hsieh, W. Y. Chen, C. H. Hsing, and M. S. Chang. 2006. IL-20: biological functions and clinical implications. J. Biomed. Sci. 13: 601-612.
20. Sa, S. M., P. A. Valdez, J. Wu, K. Jung, F. Zhong, L. Hall, I. Kasman, J. Winer, Z. Modrusan, D. M. Danilenko, and W. Ouyang. 2007. The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis. J. Immunol. 178: 2229-2240. (Pubitemid 46233421)
21. Wei, C. C., W. Y. Chen, Y. C. Wang, P. J. Chen, J. Y. Lee, T. W. Wong, W. C. Chen, J. C. Wu, G. Y. Chen, M. S. Chang, and Y. C. Lin. 2005. Detection of IL-20 and its receptors on psoriatic skin. Clin. Immunol. 117: 65-72.
22. Hsu, Y. H., H. H. Li, M. Y. Hsieh, M. F. Liu, K. Y. Huang, L. S. Chin, P. C. Chen, H. H. Cheng, and M. S. Chang. 2006. Function of interleukin-20 as a proinflammatory molecule in rheumatoid and experimental arthritis. Arthritis Rheum. 54: 2722-2733.
23. Hsu, Y. H., and M. S. Chang. 2010. Interleukin-20 antibody is a potential therapeutic agent for experimental arthritis. Arthritis Rheum. 62: 3311-3321.
24. Caligiuri, G., S. V. Kaveri, and A. Nicoletti. 2006. IL-20 and atherosclerosis: another brick in the wall. Arterioscler. Thromb. Vasc. Biol. 26: 1929-1930. (Pubitemid 44253771)
25. Chen, W. Y., B. C. Cheng, M. J. Jiang, M. Y. Hsieh, and M. S. Chang. 2006. IL-20 is expressed in atherosclerosis plaques and promotes atherosclerosis in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 26: 2090-2095.
26. Wei, C. C., H. H. Li, Y. H. Hsu, C. H. Hsing, J. M. Sung, and M. S. Chang. 2008. Interleukin-20 targets renal cells and is associated with chronic kidney disease. Biochem. Biophys. Res. Commun. 374: 448-453.
27. Li, H. H., Y. H. Hsu, C. C. Wei, P. T. Lee, W. C. Chen, and M. S. Chang. 2008. Interleukin-20 induced cell death in renal epithelial cells and was associated with acute renal failure. Genes Immun. 9: 395-404.
28. Chen, W. Y., and M. S. Chang. 2009. IL-20 is regulated by hypoxia-inducible factor and up-regulated after experimental ischemic stroke. J. Immunol. 182: 5003-5012.
29. Hsu, Y. H., W. Y. Chen, C. H. Chan, C. H. Wu, Z. J. Sun, and M. S. Chang. 2011. Anti-IL-20 monoclonal antibody inhibits the differentiation of osteoclasts and protects against osteoporotic bone loss. J. Exp. Med. 208: 1849-1861.
30. Hsieh, M. Y., W. Y. Chen, M. J. Jiang, B. C. Cheng, T. Y. Huang, and M. S. Chang. 2006. Interleukin-20 promotes angiogenesis in a direct and indirect manner. Genes Immun. 7: 234-242.
31. McClelland, R. A., P. Finlay, K. J. Walker, D. Nicholson, J. F. Robertson, R. W. Blamey, and R. I. Nicholson. 1990. Automated quantitation of immuno-cytochemically localized estrogen receptors in human breast cancer. Cancer Res. 50: 3545-3550. (Pubitemid 20194093)
32. Delaissé, J. M., T. L. Andersen, M. T. Engsig, K. Henriksen, T. Troen, and L. Blavier. 2003. Matrix metalloproteinases (MMP) and cathepsin K contribute differently to osteoclastic activities. Microsc. Res. Tech. 61: 504-513. (Pubitemid 36890583)
33. Duffy, M. J., T. M. Maguire, A. Hill, E. McDermott, and N. O'Higgins. 2000. Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res. 2: 252-257. (Pubitemid 32223594)
34. Hegedüs, L., H. Cho, X. Xie, and G. L. Eliceiri. 2008. Additional MDA-MB-231 breast cancer cell matrix metalloproteinases promote invasiveness. J. Cell. Physiol. 216: 480-485. (Pubitemid 351898476)
35. Wilson, T. J., K. C. Nannuru, and R. K. Singh. 2009. Cathepsin G-mediated activation of pro-matrix metalloproteinase 9 at the tumor-bone interface promotes transforming growth factor-beta signaling and bone destruction. Mol. Cancer Res. 7: 1224-1233.
36. Littlewood-Evans, A. J., G. Bilbe, W. B. Bowler, D. Farley, B. Wlodarski, T. Kokubo, T. Inaoka, J. Sloane, D. B. Evans, and J. A. Gallagher. 1997. The osteoclast-associated protease cathepsin K is expressed in human breast carcinoma. Cancer Res. 57: 5386-5390. (Pubitemid 27516378)
37. Le Gall, C., A. Bellahcène, E. Bonnelye, J. A. Gasser, V. Castronovo, J. Green, J. Zimmermann, and P. Clézardin. 2007. A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden. Cancer Res. 67: 9894-9902. (Pubitemid 47621238)
38. Podgorski, I., B. E. Linebaugh, J. E. Koblinski, D. L. Rudy, M. K. Herroon, M. B. Olive, and B. F. Sloane. 2009. Bone marrow-derived cathepsin K cleaves SPARC in bone metastasis. Am. J. Pathol. 175: 1255-1269.
39. Huang, K. Y., R. M. Lin, W. Y. Chen, C. L. Lee, J. J. Yan, and M. S. Chang. 2008. IL-20 may contribute to the pathogenesis of human intervertebral disc herniation. Spine 33: 2034-2040.
40. Jung, M. Y., S. H. Kim, D. Cho, and T. S. Kim. 2009. Analysis of the expression profiles of cytokines and cytokine-related genes during the progression of breast cancer growth in mice. Oncol. Rep. 22: 1141-1147.
41. Jemal, A., R. Siegel, E. Ward, T. Murray, J. Xu, and M. J. Thun. 2007. Cancer statistics, 2007. CA Cancer J. Clin. 57: 43-66. (Pubitemid 46148091)
42. Wilson, T. J., and R. K. Singh. 2008. Proteases as modulators of tumor-stromal interaction: primary tumors to bone metastases. Biochim. Biophys. Acta 1785: 85-95.
43. Wilson, T. J., K. C. Nannuru, and R. K. Singh. 2009. Cathepsin G recruits osteoclast precursors via proteolytic activation of protease-activated receptor-1. Cancer Res. 69: 3188-3195.
44. Xie, Y., W. Sheng, J. Xiang, Z. Ye, Y. Zhu, X. Chen, and J. Yang. 2008. Recombinant human IL-24 suppresses lung carcinoma cell growth via induction of cell apoptosis and inhibition of tumor angiogenesis. Cancer Biother. Radiopharm. 23: 310-320. (Pubitemid 351931460)